![Early Estimates of Bivalent mRNA Booster Dose Vaccine Effectiveness in Preventing Symptomatic SARS-CoV-2 Infection Attributable to Omicron BA.5– and XBB/XBB.1.5–Related Sublineages Among Immunocompetent Adults — Increasing Community Access to Testing ... Early Estimates of Bivalent mRNA Booster Dose Vaccine Effectiveness in Preventing Symptomatic SARS-CoV-2 Infection Attributable to Omicron BA.5– and XBB/XBB.1.5–Related Sublineages Among Immunocompetent Adults — Increasing Community Access to Testing ...](https://www.cdc.gov/mmwr/volumes/72/wr/social-media/mm7205e1_BivalentVECurrentSublineages_IMAGE_25Jan2023_1200x675-medium.jpg?_=95835)
Early Estimates of Bivalent mRNA Booster Dose Vaccine Effectiveness in Preventing Symptomatic SARS-CoV-2 Infection Attributable to Omicron BA.5– and XBB/XBB.1.5–Related Sublineages Among Immunocompetent Adults — Increasing Community Access to Testing ...
![Vaccines | Free Full-Text | Vaccine Confidence and Uptake of the Omicron Bivalent Booster in Tennessee: Implications for Vulnerable Populations Vaccines | Free Full-Text | Vaccine Confidence and Uptake of the Omicron Bivalent Booster in Tennessee: Implications for Vulnerable Populations](https://www.mdpi.com/vaccines/vaccines-11-00906/article_deploy/html/images/vaccines-11-00906-g001-550.jpg)
Vaccines | Free Full-Text | Vaccine Confidence and Uptake of the Omicron Bivalent Booster in Tennessee: Implications for Vulnerable Populations
![ATAGI statement on use of the Moderna bivalent Original/Omicron vaccine | Australian Government Department of Health and Aged Care ATAGI statement on use of the Moderna bivalent Original/Omicron vaccine | Australian Government Department of Health and Aged Care](https://www.health.gov.au/sites/default/files/styles/h_content_max_width_no_upscale/public/images/news/2022/09/atagi-statement-on-use-of-the-moderna-bivalent-original-omicron-vaccine.png?itok=BIYw_3RB)
ATAGI statement on use of the Moderna bivalent Original/Omicron vaccine | Australian Government Department of Health and Aged Care
![Effectiveness of Bivalent mRNA Vaccines in Preventing Symptomatic SARS-CoV-2 Infection — Increasing Community Access to Testing Program, United States, September–November 2022 | MMWR Effectiveness of Bivalent mRNA Vaccines in Preventing Symptomatic SARS-CoV-2 Infection — Increasing Community Access to Testing Program, United States, September–November 2022 | MMWR](https://www.cdc.gov/mmwr/volumes/71/wr/social-media/mm7148e1-BivalentBooster_IMAGE_22NOV2022_1200x675.jpg?_=65732)
Effectiveness of Bivalent mRNA Vaccines in Preventing Symptomatic SARS-CoV-2 Infection — Increasing Community Access to Testing Program, United States, September–November 2022 | MMWR
![Second bivalent booster: Sandra Fryhofer, MD, on who should get another COVID shot and when - YouTube Second bivalent booster: Sandra Fryhofer, MD, on who should get another COVID shot and when - YouTube](https://i.ytimg.com/vi/ZlrewJP4e5g/maxresdefault.jpg)
Second bivalent booster: Sandra Fryhofer, MD, on who should get another COVID shot and when - YouTube
![Relative effectiveness of monovalent and bivalent mRNA boosters in preventing severe COVID-19 due to omicron BA.5 infection up to 4 months post-administration in people aged 60 years or older in Italy: a Relative effectiveness of monovalent and bivalent mRNA boosters in preventing severe COVID-19 due to omicron BA.5 infection up to 4 months post-administration in people aged 60 years or older in Italy: a](https://www.thelancet.com/cms/attachment/b611936d-5800-49ea-ab56-e932ddaa3aa7/gr1_lrg.jpg)
Relative effectiveness of monovalent and bivalent mRNA boosters in preventing severe COVID-19 due to omicron BA.5 infection up to 4 months post-administration in people aged 60 years or older in Italy: a
![LVHN Offering Second Dose of Bivalent COVID-19 Booster Shot for Both 65+ and Immunocompromised People LVHN Offering Second Dose of Bivalent COVID-19 Booster Shot for Both 65+ and Immunocompromised People](https://www.lvhn.org/sites/default/files/2023-05/N23855_Bivalent%20Booster%20Update-Press%20Release.jpg)